RPG LIFE SCIENCES LIMITED
Regd. Off.: RPG House
463, Dr. Annie Besant Road
Worli, Mumbai 400030, India
Tel: +91-22-24981650 / 66606375
Fax: +91-22-24970127
Email: info@rpglifesciences.com
www.rpglifesciences.com
CIN : L24232MH2007PLC169354

September 2, 2026

National Stock Exchange of India Limited
Plot No. C/1, "G" Block, Exchange Plaza,
Bandra Kurla Complex, Bandra (East),
Mumbai 400 051

Symbol: RPGLIFE

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

Security Code: 532983

Dear Sirs,

<u>Sub: Investors Presentation</u>

In continuation to our letter dated September 2, 2026 informing Analyst/Institutional Investors meeting, please find enclosed herewith a copy of Investors Presentation.

Kindly take the above on record.

Thanking you,

Yours Sincerely,
For RPG Life Sciences Limited

RAJESH
RAMESH
SHIRAMBEKAR

Digitally signed by
RAJESH RAMESH
SHIRAMBEKAR
Date: 2026.09.02
22:32:03 +05'30'

Rajesh Shirambekar
Head- Legal & Company Secretary

Encl: as above

RPG Life Sciences

RPG Active Pharma – Transaction Update

02nd September, 2026

RPG LIFE SCIENCES

A Subsidiarization of API business into RPGAP for strategic focus



API business

- The API business operates from state-of-the-art facility located at Navi Mumbai
- Focused on high-value low-volume niche products which ware fairly insulated from price commoditization and Chinese competition.
- Growing product pipeline with strong R&D focus
- Strong team being put into place led by CEO with deep experience at industry majors like Teva, DRL, UPL etc. and supported by dedicated management team with CXOs having strong industry pedigree
- External (third-party) sales of ~95.1 Cr INR in FY26, apart from captive sales to RPGLS for Formulations Business
- The subsidiarization was completed via Business Transfer Agreement i.e. slump sale mechanism
- There is a Supply Services and Transition agreement towards continuing captive sales, shared services and transition support

B Partnership with pharma-centric PE firm InvAscent for value creation



Invascent (Investor)

- InvAscent is one of India's most specialised pharma-centric Private Equity firm bringing in over 20 years of experience of building businesses in formulations, API, healthcare delivery, medtech, animal health and health-tech
- Total AUM of USD 850 Mn+ across 4 funds trusted by marquee investors from across the globe
- InvAscent as a partner brings in growth capital, deep sectoral knowledge with strong industry relationships
- Partnership expected to yield benefits in terms of product selection, M&A, customer connects, cross-sell synergies and sharper focus on API amongst other positives
- This shall enable RPGAP to lead the next stage of growth story and accelerate value creation

Note: The above structure shall come into effect upon closing of the Investment and shareholders' agreement dated 29th July 2026

C Acquisition of Actis Generics by RPGAP for enhancing Product Portfolio



Actis Generics

- Actis is a fully backward-integrated manufacturer of API and complex intermediates based out of Vizag (AP)
- Manufacturing facility is in Visakha Pharma City which provides all the benefits of a specialized pharmaceutical production area
- The manufacturing facility is running at close to full capacity with possibility of expansion at site
- Highly technical multi-step manufacturing processes with an established price competitive position in key molecules
- Anti-Diabetic and Cardiology focused product portfolio with increasingly growing demand
- Established long-standing relations with marquee customers

Note: The above structure shall come into effect upon closing of the Share Purchase Agreement dated 29th July 2026

D Acquisition of Raghava Life Sciences for enhancing Capacity and Product Portfolio



Raghava Life Sciences

- State-of-the-art manufacturing facility located close to Hyderabad spread over 9 Acres and a large installed capacity of 300 KL.
- The facility is maintained impeccably with new block built over the past 3 years
- Backward integration - API and intermediates
- Significant R&D spend over the last few years – Portfolio of 29 API molecules of which 22 are commercialized and 7 are under development
- Secured WHO GMP, EU GMP; KDMF and CEP approvals
- Revenue and cost synergy potential with Actis and RPGAP
- Transaction provides access to certain marquee customer relationships
- Plant's revenue potential of about 200 Cr INR at full utilization levels

Note: The above structure shall come into effect upon closing of the Business Transfer Agreement dated 02nd Sep 2026

RPG Active Pharma – strategic readiness in all aspects for future growth

RPG ACTIVE PHARMA

Product
- Niche products with strong demand outlook
- Stringent product selection criteria for high margin focus

Partnership
- Partnered with pharma focussed Investor
- Sharper focus on API, industry connects

R&D
- R&D focus with new product development and cost optimisation initiatives
- Building deeper R&D expertise with dedicated R&D centre

Manufacturing
- State-of-the art factories future ready installed capacity (increased by 4x)
- Backward integration and high level of process optimisation
- Ability to leverage economies of scale

Capital
- Sufficient liquidity to pursue organic and inorganic growth
- Zero debt company with prudent leverage runway

Customers
- Long-standing customer relationships
- Fast expanding customer base with acquisitions

Talent
- Onboarded CEO with deep industry expertise
- Highly qualified and experienced team, building further


THANK YOU
RPG LIFE SCIENCES